p53 expression as a prognostic marker in inflammatory breast cancer
| Autor: | Kristine Broglio, Yuko Yamamura, Massimo Cristofanilli, Shu Wan Kau, Nour Sneige, Aman U. Buzdar, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Vicente Valero |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Time Factors Anthracycline Paclitaxel Breast Neoplasms Inflammatory breast cancer Disease-Free Survival chemistry.chemical_compound Breast cancer Internal medicine medicine Humans Pathological Aged Retrospective Studies Cell Nucleus business.industry Age Factors Middle Aged medicine.disease Genes p53 Prognosis Immunohistochemistry Surgery Regimen Treatment Outcome chemistry Hormone receptor Female Tumor Suppressor Protein p53 business |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research. 10(18 Pt 1) |
| ISSN: | 1078-0432 |
| Popis: | Purpose: Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Nuclear expression of p53 protein in breast cancer correlates with more aggressive tumors. We retrospectively analyze the expression of p53 as a prognostic marker to predict pathological complete response and survival in patients with IBC. Experimental Design: Fifty-nine patients with IBC were treated from January 1994 to April 2000. Forty-eight patients were included. Diagnostic core biopsies were taken before treatment was started. Expression of hormone receptors and p53 was determined by immunohistochemistry. All patients received an anthracycline-based regimen preoperatively; 22 patients (46%) also received paclitaxel. Forty-four patients (92%) achieved an objective clinical response and underwent mastectomies. Results: Median age at diagnosis was 48 years. Thirty patients (63%) had hormone receptor-negative tumors. Twenty-eight patients (58%) had p53-positive tumors, and 20 patients (42%) had p53-negative tumors. Nine patients (19%) achieved a pathological complete response. At a median follow-up of 77 months, 28 recurrences (58%) and 26 deaths (54%) had occurred. Patients with p53-positive tumors were younger (P = 0.02) and tended to have lower 5-year progression-free survival rates (35% versus 55%; P = 0.3) and overall survival rates (44% versus 54%; P = 0.4). Conclusions: This retrospective analysis demonstrates that nuclear p53 protein expression may represent an adverse prognostic marker in IBC and may provide a valuable tool for selecting treatment for this aggressive disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|